Related Experiment Videos
Ticarcillin therapy of risk patients with infections due to Pseudomonas aeruginosa
Abstract:
The implication of nosocomial infection due to Pseudomonas aeruginosa is demonstrated by comparing the bacteriological findings with the clinical picture of ten patients in a surgical intensive care unit. The occurrence of this organism and its resistance to beta-lactam-antibiotics and aminoglycosides is demonstrated. Ticarcillin was administered to ten patients following bacteriological and clinical evidence of infections due to P. aeruginosa. The pathogenicity of P. aeruginosa as an organism complicating the course of severely injured patients is discussed. Therapeutic consequences in regard to possible combination with other antibiotics are suggested.
Insights
Nosocomial infections from Pseudomonas aeruginosa are common in surgical ICUs. This study highlights its antibiotic resistance and suggests combination therapies for better treatment outcomes.
Area of Science:
- Infectious Diseases
- Clinical Microbiology
- Critical Care Medicine
Background:
- Nosocomial infections pose significant risks in intensive care units.
- Pseudomonas aeruginosa is a common pathogen in healthcare settings.
- Antibiotic resistance in P. aeruginosa complicates treatment strategies.
Observation:
- Bacteriological findings were correlated with clinical presentations in ten surgical ICU patients.
- The study observed the prevalence of P. aeruginosa.
- Resistance patterns against beta-lactam antibiotics and aminoglycosides were noted.
Findings:
- Pseudomonas aeruginosa infections were identified in ten surgical ICU patients.
- Ticarcillin treatment was initiated based on confirmed P. aeruginosa infections.
- The pathogenicity of P. aeruginosa in severely injured patients was evident.
Implications:
- P. aeruginosa complicates the course of critically ill patients.
- Combination antibiotic therapy may be necessary for effective treatment.
- Understanding resistance patterns is crucial for guiding therapeutic choices.